| 75.49 0.09 (0.12%) | 08-15 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term | |
|||
| Targets | 6-month : | 1-year : | ||
| Resists | First : | Second : | ||
| Pivot price | ||||
| Supports | First : | Second : | ||
| MAs | MA(5) : | MA(20) : | ||
| MA(100) : | MA(250) : | |||
| MACD | MACD : | Signal : | ||
| %K %D | K(14,3) : | D(3) : | ||
| RSI | RSI(14): | |||
| 52-week | High : | Low : | ||
| If tomorrow: | Open lower | Open higher |
| High: | - | - |
| Low: | - | - |
| Close: | - | - |
Turning Point Therapeutics is a biopharmaceutical firm specializing in precision oncology, currently in the clinical development stage. The company is dedicated to discovering and advancing targeted therapies that address the underlying genetic causes of cancer. They have developed a portfolio of innovative tyrosine kinase inhibitors (TKIs) designed to treat cancer patients, including those who have not yet received TKI treatment and those who have previously been treated with TKIs. Their flagship experimental compound, repotrectinib, is currently undergoing evaluation in the Phase 1/2 TRIDENT-1 clinical study. This trial is aimed at individuals with advanced non-small-cell lung cancer (NSCLC) characterized by ROS1 positivity, as well as those with advanced solid tumors exhibiting ROS1 and NTRK mutations. The company's developmental pipeline further includes TPX-0022, a MET/SRC/CSF1R inhibitor, which is in a Phase 1 SHIELD-1 trial for advanced solid tumors carrying MET genetic abnormalities. Additionally, TPX-0046, a RET inhibitor, is progressing through its Phase 1/2 SWORD-1 clinical trial for advanced solid tumors with RET genetic variations. Finally, TPX-0131, an ALK inhibitor, is being investigated in the Phase 1/2 FORGE-1 study for patients with advanced or metastatic ALK-positive NSCLC who have previously undergone TKI therapy. Established in San Diego, California, in 2013, Turning Point Therapeutics became a subsidiary of Bristol-Myers Squibb Company on August 15, 2022.
Tue, 26 May 2026
Turning Point Therapeutics Inc (TPTX) - Minichart
Mon, 13 Jun 2022
Bristol Myers Squibb Buys Turning Point - San Diego Business Journal
Fri, 03 Jun 2022
UPDATE: Bristol Myers strikes up Roche rivalry with $4.1B Turning Point buy - Fierce Biotech
Fri, 03 Jun 2022
Bristol Myers Squibb to Acquire Turning Point Therapeutics - citybiz
Fri, 03 Jun 2022
Bristol Myers Squibb to Acquire Turning Point Therapeutics, a Leading Precision Oncology Company - Business Wire
Fri, 03 Jun 2022
Why Bristol-Myers Squibb (BMY) Is Buying Turning Point Therapeutics (TPTX) In A $4.1 Billion Deal - Pulse 2.0
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 0 (M) |
| Shares Float | 0 (M) |
| Held by Insiders | (%) |
| Held by Institutions | (%) |
| Shares Short | 0 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | |
| EPS Est Next Qtrly | |
| EPS Est This Year | |
| EPS Est Next Year | |
| Book Value (p.s.) | |
| Profit Margin | % |
| Operating Margin | % |
| Return on Assets (ttm) | % |
| Return on Equity (ttm) | % |
| Qtrly Rev. Growth | % |
| Gross Profit (p.s.) | |
| Sales Per Share | |
| EBITDA (p.s.) | |
| Qtrly Earnings Growth | % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | |
| PEG Ratio | |
| Price to Book value | |
| Price to Sales | |
| Price to Cash Flow |
| Dividend | |
| Forward Dividend | |
| Dividend Yield | 0% |
| Dividend Pay Date | |
| Ex-Dividend Date |
|
|
|
|
|
|
|
|
|